Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
University of Pittsburgh · University of Bologna · +25 more institutions
Abstract
Although growing evidence points to highly indolent behavior of encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), most patients with EFVPTC are treated as having conventional thyroid cancer.
To evaluate clinical outcomes, refine diagnostic criteria, and develop a nomenclature that appropriately reflects the biological and clinical characteristics of EFVPTC. DESIGN, SETTING, AND PARTICIPANTS: International, multidisciplinary, retrospective study of patients with thyroid nodules diagnosed as EFVPTC, including 109 patients with noninvasive EFVPTC observed for 10 to 26 years and 101 patients with invasive EFVPTC observed for 1 to 18 years. Review of digitized histologic slides collected at 13 sites in 5 countries by 24 thyroid pathologists from 7 countries. A series of teleconferences and a face-to-face conference were used to establish consensus diagnostic criteria and develop new nomenclature. MAIN OUTCOMES AND MEASURES: Frequency of adverse outcomes, including death from disease, distant or locoregional metastases, and structural or biochemical recurrence, in patients with noninvasive and invasive EFVPTC diagnosed on the basis of a set of reproducible histopathologic criteria.
Citation impact
- FWCI
- 172.66
- Percentile
- 100%
- References
- 39
Authors
31Topics & keywords
- Medicine
- Thyroid carcinoma
- Thyroid
- Thyroid cancer
- Thyroid nodules
- Papillary thyroid cancer
- Radiology
- Follicular thyroid cancer
- Partnerships for the goals
Funding
- MGMassachusetts General Hospital
- TMTufts Medical Center
- MSMemorial Sloan-Kettering Cancer Center
- MEMassachusetts Eye and Ear
- UOUniversity of Pittsburgh
- UOUniversity of Portsmouth
- YUYork University
- UDUniversità degli Studi di Torino
- SOSchool of Medicine, New York University
- SOSchool of Medicine and Public Health, University of Wisconsin-Madison
- TUTufts University School of Medicine
- CICancer Institute, University of Pittsburgh